{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-103707","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.135378+00:00","generated_at":"2026-05-17T01:22:07.969924+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ENDRA Life Sciences enters ATM equity facility for up to $1.75M through Lucid Capital Markets","bullets":["Aggregate gross proceeds up to $1,750,000 from sale of common stock at-the-market.","Lucid Capital Markets acts as sales agent with a 3.0% commission on gross proceeds.","Sales may be made directly on Nasdaq Capital Market or in negotiated transactions.","Agreement effective October 29, 2025; terminates upon full sale, earlier termination, or 3-year anniversary.","Company has no obligation to sell any shares and may suspend or terminate at any time."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-103707","json":"https://secwatch.observer/filing/0001213900-25-103707.json","markdown":"https://secwatch.observer/filing/0001213900-25-103707.md","text":"https://secwatch.observer/filing/0001213900-25-103707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000121390025103707/0001213900-25-103707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000121390025103707/ea0263059-8k_endra.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:22:07.969924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}